V503 + Gardasil
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections
Trial Timeline
Jun 26, 2019 → Mar 31, 2028
NCT ID
NCT03998254About V503 + Gardasil
V503 + Gardasil is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is active. This product is registered under clinical trial identifier NCT03998254. Target conditions include Papillomavirus Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03998254 | Phase 3 | Active |
| NCT02653118 | Pre-clinical | Active |
| NCT02114385 | Phase 3 | Completed |
| NCT01304498 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections